GLP-1 NAION (Semaglutide Vision Loss) US
MDL ConsolidatedCompany record in this matter
Novo Nordisk (Ozempic, Wegovy, Rybelsus) is the primary defendant in the GLP-1 NAION wave. Novo-specific claims center on semaglutide labeling and the company’s response to adverse-event reports. Novo’s 2023 DOJ deferred-prosecution agreement (unrelated to NAION) is documented in the company’s regulatory history.
Full case record
Court details, case count history, key dates, filings, sources and FAQ are on the main case page:
Frequently asked questions
Is Novo Nordisk being sued in GLP-1 NAION (Semaglutide Vision Loss)?
Yes — Novo Nordisk is listed among the companies in this matter. Status as of 2026-09-01: mdl_consolidated. The full case record has the court, docket and all key dates.
What is the status of GLP-1 NAION (Semaglutide Vision Loss)?
As of 2026-09-01, the matter is in the “mdl_consolidated” stage with 120 cases on the record. Every change is logged in the case record's updates section with its source.
Where can I see the full record for GLP-1 NAION (Semaglutide Vision Loss)?
The main case page has the full record: court and judge, case count history, key dates, filings, settlement amounts where published, and sources. It is linked at the top of this section.
About the company
Regulatory history, violations, and every tracked case for Novo Nordisk →
Think this matters to you?
This is reference material — not legal advice. Start a free case review.
Start free case review →